Biocartis develops rapid Ebola triage test with Janssen Diagnostics

Biocartis CEO Rudi Pauwels

As diagnostics companies zero in on rapid tests to counter the deadly Ebola outbreak, Biocartis is developing a quick triage test for the virus. Biocartis, along with business partner Janssen Diagnostics and the Institute for Tropical Medicine in Antwerp, is designing a product that runs on its Idylla automated molecular diagnostic platform and can complete an analysis in around 90 minutes. The test can be performed in the field, making it suitable for use in areas with limited infrastructure. "One of the lessons of the Ebola outbreak has been the urgent need for faster and more accurate diagnostics," Rudi Pauwels, Biocartis CEO, said in a statement. "Biocartis is pleased to be working, alongside prestigious partners, on what I believes could offer a viable solution for healthcare workers around the world to enable faster testing of infectious diseases in virtually any setting." Statement

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.